Normal tissue protection for improving radiotherapy: Where are the Gaps?

Translational Cancer Research

Volumn 1, Issue 1, 2012, Pages 35-48

  Prasanna, Pataje G S ^a   Stone, Helen B ^a   Wong, Rosemary S ^a   Capala, Jacek ^a   Bernhard, Eric J ^a   Vikram, Bhadrasain ^a   Coleman, C N ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Acute radiation effects; Lung fibrosis; Oral mucositis; Radiation mitigator; Radiation induced brain damage; Radioprotector; Radiotherapy

Indexed keywords

EID: 84962709333     PISSN: 2218676X     EISSN: 22196803     Source Type: Journal    
DOI: 10.3978/j.issn.2218-676X.2012.05.05     Document Type: Review

References (83)

1. Vikram B, Coleman CN, Deye JA. Current status and future potential of advanced technologies in radiation oncology. Part 1. Challenges and resources. Oncology 2009;23:279-83. Williston Park.
2. Dorr W, Hendry JH. Consequential late effects in normal tissues. Radiother Oncol 2001;61:223-31.
3. Johannesen TB, Lien HH, Hole KH, et al. Radiological and clinical assessment of long-term brain tumour survivors after radiotherapy. Radiother Oncol 2003;69:169-76.
4. Coleman CN, Blakely WF, Fike JR, et al. Molecular and cellular biology of moderate-dose (1-10 Gy) radiation and potential mechanisms of radiation protection: report of a workshop at Bethesda, Maryland, December 17-18, 2001. Radiat Res 2003;159:812-34.
5. Rose-Ped AM, Bellm LA, Epstein JB, et al. Complications of radiation therapy for head and neck cancers. The patient's perspective. Cancer Nurs 2002;25:461-7.
6. Bellm LA, Epstein JB, Rose-Ped A, et al. Patient reports of complications of bone marrow transplantation. Support Care Cancer 2000;8:33-9.
7. Nonzee NJ, Dandade NA, Patel U, et al. Evaluating the supportive care costs of severe radiochemotherapyinduced mucositis and pharyngitis: results from a Northwestern University Costs of Cancer Program pilot study with head and neck and nonsmall cell lung cancer patients who received care at a county hospital, a Veterans Administration hospital, or a comprehensive cancer care center. Cancer 2008;113:1446-52.
8. Raber-Durlacher JE, Elad S, Barasch A. Oral mucositis. Oral Oncol 2010;46:452-6.
9. World Health Organization. WHO handbook for reporting results of cancer treatment. Geneva, [Albany, N.Y.: World Health Organization; sold by WHO Publications Centre USA]; 1979.
10. Sonis ST. Mucositis as a biological process: a new hypothesis for the development of chemotherapy-induced stomatotoxicity. Oral Oncol 1998;34:39-43.
11. Rubin P, Johnston CJ, Williams JP, et al. A perpetual cascade of cytokines postirradiation leads to pulmonary fibrosis. Int J Radiat Oncol Biol Phys 1995;33:99-109.
12. Sonis ST. A biological approach to mucositis. J Support Oncol 2004;2:21-32.
13. Russo G, Haddad R, Posner M, et al. Radiation treatment breaks and ulcerative mucositis in head and neck cancer. Oncologist 2008;13:886-98.
14. Spielberger R, Stiff P, Bensinger W, et al. Palifermin for oral mucositis after intensive therapy for hematologic cancers. N Engl J Med 2004;351:2590-8.
15. Kim JH, Chu FC, Lakshmi V, et al. Benzydamine HCl, a new agent for the treatment of radiation mucositis of the oropharynx. Am J Clin Oncol 1986;9:132-4.
16. Sonis ST, Clairmont F, Lockhart PB, et al. Benzydamine HCL in the management of chemotherapy-induced mucositis. I. Pilot study. J Oral Med 1985;40:67-71.
17. Brizel DM, Wasserman TH, Henke M, et al. Phase III randomized trial of amifostine as a radioprotector in head and neck cancer. J Clin Oncol 2000;18:3339-45.
18. Rosen LS, Abdi E, Davis ID, et al. Palifermin reduces the incidence of oral mucositis in patients with metastatic colorectal cancer treated with fluorouracil-based chemotherapy. J Clin Oncol 2006;24:5194-200.
19. Brizel DM, Murphy BA, Rosenthal DI, et al. Phase II study of palifermin and concurrent chemoradiation in head and neck squamous cell carcinoma. J Clin Oncol 2008;26:2489-96.
20. Le QT, Kim HE, Schneider CJ, et al. Palifermin reduces severe mucositis in definitive chemoradiotherapy of locally advanced head and neck cancer: a randomized, placebocontrolled study. J Clin Oncol 2011;29:2808-14.
21. Yen SH, Wang LW, Lin YH, et al. Phenylbutyrate mouthwash mitigates oral mucositis during radiotherapy or chemoradiotherapy in patients with head-and-neck cancer. Int J Radiat Oncol Biol 2012;82:463-70.
22. Tyldesley S, Boyd C, Schulze K, et al. Estimating the need for radiotherapy for lung cancer: an evidence-based, epidemiologic approach. Int J Radiat Oncol Biol Phys 2001;49:973-85.
23. Stone HB, Coleman CN, Anscher MS, et al. Effects of radiation on normal tissue: consequences and mechanisms. Lancet Oncol 2003;4:529-36.
24. Anscher MS, Kong FM, Marks LB, et al. Changes in plasma transforming growth factor beta during radiotherapy and the risk of symptomatic radiation-induced pneumonitis. Int J Radiat Oncol Biol Phys 1997;37:253-8.
25. Yuan X, Liao Z, Liu Z, et al. Single nucleotide polymorphism at rs1982073:T869C of the TGFbeta 1 gene is associated with the risk of radiation pneumonitis in patients with non-small-cell lung cancer treated with definitive radiotherapy. J Clin Oncol 2009;27:3370-8.
26. Chen Y, Williams J, Ding I, et al. Radiation pneumonitis and early circulatory cytokine markers. Semin Radiat Oncol 2002;12:26-33.
27. Kong FM, Ten Haken R, Eisbruch A, et al. Non-small cell lung cancer therapy-related pulmonary toxicity: an update on radiation pneumonitis and fibrosis. Semin Oncol 2005;32:S42-S54.
28. Greenberger JS. Gene therapy approaches for stem cell protection. Gene Ther 2008;15:100-8.
29. Marks LB, Bentzen SM, Deasy JO, et al. Radiation dosevolume effects in the lung. Int J Radiat Oncol Biol Phys 2010;76(Suppl):S70-6.
30. Kong FM, Ten Haken RK, Schipper MJ, et al. High-dose radiation improved local tumor control and overall survival in patients with inoperable/unresectable non-small-cell lung cancer: long-term results of a radiation dose escalation study. Int J Radiat Oncol Biol Phys 2005;63:324-33.
31. Kouroussis C, Mavroudis D, Kakolyris S, et al. High incidence of pulmonary toxicity of weekly docetaxel and gemcitabine in patients with non-small cell lung cancer: results of a dosefinding study. Lung Cancer 2004;44:363-8.
32. Hill RP, Zaidi A, Mahmood J, Jelveh S. Investigations into the role of inflammation in normal tissue response to irradiation. Radiother Oncol 2011;101:73-9.
33. Skwarchuk MW, Travis EL. Murine strain differences in the volume effect and incidence of radiation-induced colorectal obstruction. Int J Radiat Oncol Biol Phys 1998;41:889-95.
34. Sarna L, Swann S, Langer C, et al. Clinically meaningful differences in patient-reported outcomes with amifostine in combination with chemoradiation for locally advanced non-small-cell lung cancer: an analysis of RTOG 9801. Int J Radiat Oncol Biol Phys 2008;72:1378-84.
35. Robbins ME, Diz DI. Pathogenic role of the reninangiotensin system in modulating radiation-induced late effects. Int J Radiat Oncol Biol Phys 2006;64:6-12.
36. Lavoie JL, Sigmund CD. Minireview: overview of the renin-angiotensin system-an endocrine and paracrine system. Endocrinology 2003;144:2179-83.
37. Nakajima M, Hutchinson HG, Fujinaga M, et al. The angiotensin II type 2 (AT2) receptor antagonizes the growth effects of the AT1 receptor: gain-of-function study using gene transfer. Proc Natl Acad Sci USA 1995;92:10663-7.
38. Molteni A, Wolfe LF, Ward WF, et al. Effect of an angiotensin II receptor blocker and two angiotensin converting enzyme inhibitors on transforming growth factor-beta (TGF-beta) and alpha-actomyosin (alpha SMA), important mediators of radiation-induced pneumopathy and lung fibrosis. Curr Pharm Des 2007;13:1307-16.
39. Kharofa J, Cohen EP, Tomic R, et al. Decreased Risk of Radiation Pneumonitis with Incidental Concurrent Use of Angiotensin-Converting Enzyme Inhibitors and Thoracic Radiation Therapy. Int J Radiat Oncol Biol Phys. DOI:S0360-3016(11)03501-2[pii]10.1016/j.ijrobp.2011.11.013.
40. Wang LW, Fu XL, Clough R, et al. Can angiotensinconverting enzyme inhibitors protect against symptomatic radiation pneumonitis? Radiat Res 2000;153:405-10.
41. Day RM, Barshishat-Kupper M, Mog SR, et al. Genistein protects against biomarkers of delayed lung sequelae in mice surviving high-dose total body irradiation. J Radiat Res (Tokyo) 2008;49:361-72.
42. Calveley VL, Jelveh S, Langan A, et al. Genistein can mitigate the effect of radiation on rat lung tissue. Radiat Res 2010;173:602-11.
43. Greenberger JS, Epperly MW. Review. Antioxidant gene therapeutic approaches to normal tissue radioprotection and tumor radiosensitization. In Vivo 2007;21:141-6.
44. Carpenter M, Epperly MW, Agarwal A, et al. Inhalation delivery of manganese superoxide dismutase-plasmid/liposomes protects the murine lung from irradiation damage. Gene Ther 2005;12:685-93.
45. Guo H, Epperly MW, Bernarding M, et al. Manganese superoxide dismutase-plasmid/liposome (MnSOD-PL) intratracheal gene therapy reduction of irradiation-induced inflammatory cytokines does not protect orthotopic Lewis lung carcinomas. In Vivo 2003;17:13-21.
46. Rosenman J. Can the use of amifostine improve cure rates for patients with advanced non-small cell lung cancer? Semin Oncol 2004;31:52-8.
47. American Cancer Society I. Learn about cancer. American Cancer Society; 2012 [updated 01/05/2012; cited 2012 05/05/2012]; Available from: http://www.cancer.org/Cancer/BrainCNSTumorsinAdults/DetailedGuide/brainand-spinal-cord-tumors-in-adults-key-statistics.
48. Kim JH, Brown SL, Jenrow KA, et al. Mechanisms of radiation-induced brain toxicity and implications for future clinical trials. J Neurooncol 2008;87:279-86.
49. Ramanan S, Kooshki M, Zhao W, et al. The PPARalpha agonist fenofibrate preserves hippocampal neurogenesis and inhibits microglial activation after whole-brain irradiation. Int J Radiat Oncol Biol Phys 2009;75:870-7.
50. Limoli CL, Rola R, Giedzinski E, et al. Cell-densitydependent regulation of neural precursor cell function. Proc Natl Acad Sci USA 2004;101:16052-7.
51. Limoli CL, Giedzinski E, Rola R, et al. Radiation response of neural precursor cells: linking cellular sensitivity to cell cycle checkpoints, apoptosis and oxidative stress. Radiat Res 2004;161:17-27.
52. Raber J, Rola R, LeFevour A, et al. Radiation-induced cognitive impairments are associated with changes in indicators of hippocampal neurogenesis. Radiat Res 2004;162:39-47.
53. Coderre JA, Morris GM, Micca PL, et al. Late effects of radiation on the central nervous system: role of vascular endothelial damage and glial stem cell survival. Radiat Res 2006;166:495-503.
54. Otsuka S, Coderre JA, Micca PL, et al. Depletion of neural precursor cells after local brain irradiation is due to radiation dose to the parenchyma, not the vasculature. Radiat Re 2006;165:582-91.
55. Robbins ME, Zhao W. Chronic oxidative stress and radiation-induced late normal tissue injury: a review. Int J Radiat Biol 2004;80:251-9.
56. Schuller BW, Binns PJ, Riley KJ, et al. Selective irradiation of the vascular endothelium has no effect on the survival of murine intestinal crypt stem cells. Proc Natl Acad Sci USA 2006;103:3787-92.
57. Li YQ, Ballinger JR, Nordal RA, et al. Hypoxia in radiation-induced blood-spinal cord barrier breakdown. Cancer Res 2001;61:3348-54.
58. McKinley MJ, Albiston AL, Allen AM, et al. The brain renin-angiotensin system: location and physiological roles. Int J Biochem Cell Biol 2003;35:901-18.
59. Gard PR. The role of angiotensin II in cognition and behaviour. Eur J Pharmacol 2002;438:1-14.
60. Kim JH, Brown SL, Kolozsvary A, et al. Modification of radiation injury by ramipril, inhibitor of angiotensinconverting enzyme, on optic neuropathy in the rat. Radiat Res 2004;161:137-42.
61. Ryu S, Kolozsvary A, Jenrow KA, et al. Mitigation of radiation-induced optic neuropathy in rats by ACE inhibitor ramipril: importance of ramipril dose and treatment time. J Neurooncol 2007;82:119-24.
62. Robbins ME, Zhao W, Garcia-Espinosa MA, et al. Reninangiotensin system blockers and modulation of radiationinduced brain injury. Curr Drug Targets 2010;11:1413-22.
63. Conner KR, Payne VS, Forbes ME, et al. Effects of the AT1 receptor antagonist L-158,809 on microglia and neurogenesis after fractionated whole-brain irradiation. Radiat Res 2010;173:49-61.
64. Robbins ME, Payne V, Tommasi E, et al. The AT1 receptor antagonist, L-158,809, prevents or ameliorates fractionated whole-brain irradiation-induced cognitive impairment. Int J Radiat Oncol Biol Phys 2009;73:499-505.
65. Lu D, Goussev A, Chen J, et al. Atorvastatin reduces neurological deficit and increases synaptogenesis, angiogenesis, and neuronal survival in rats subjected to traumatic brain injury. J Neurotrauma 2004;21:21-32.
66. Shishehbor MH, Brennan ML, Aviles RJ, et al. Statins promote potent systemic antioxidant effects through specific inflammatory pathways. Circulation 2003;108:426-31.
67. Shishehbor MH, Patel T, Bhatt DL. Using statins to treat inflammation in acute coronary syndromes: Are we there yet? Cleve Clin J Med 2006;73:760-6.
68. Chen J, Zhang ZG, Li Y, et al. Statins induce angiogenesis, neurogenesis, and synaptogenesis after stroke. Ann Neurol 2003;53:743-51.
69. Jenrow KA, Liu J, Brown SL, et al. Combined atorvastatin and ramipril mitigate radiation-induced impairment of dentate gyrus neurogenesis. J Neurooncol 2011;101:449-56.
70. Winkler F, Kozin SV, Tong RT, et al. Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases. Cancer Cell 2004;6:553-63.
71. Gonzalez J, Kumar AJ, Conrad CA, et al. Effect of bevacizumab on radiation necrosis of the brain. Int J Radiat Oncol Biol Phys 2007;67:323-6.
72. Movsas B, Vikram B, Hauer-Jensen M, et al. Decreasing the adverse effects of cancer therapy: National Cancer Institute guidance for the clinical development of radiation injury mitigators. Clin Cancer Res 2011;17:222-8.
73. Ryan JL, Krishnan S, Movsas B, et al. Decreasing the adverse effects of cancer therapy: an NCI Workshop on the preclinical development of radiation injury mitigators/protectors. Radiat Res 2011;176;688-91.
74. Yuhas JM, Afzal SM, Afzal V. Variation in normal tissue responsiveness to WR-2721. Int J Radiat Oncol Biol Phys 1984;10:1537-9.
75. Rane N, Quaghebeur G. CNS effects following the treatment of malignancy. Clin Radiol 2012;67:61-8.
76. Sonis ST. Mucositis: The impact, biology and therapeutic opportunities of oral mucositis. Oral Oncol 2009;45:1015-20.
77. Matuschek C, Bolke E, Nawatny J, et al. Bevacizumab as a treatment option for radiation-induced cerebral necrosis. Strahlenther Onkol 2011;187:135-9.
78. Thompson LH, Suit HD. Proliferation kinetics of x-irradiated mouse L cells studied with time-lapse photography. Int J Radiat Biol Relat Stud Phys Chem Med 1969;15:347-62.
79. Brown JM, Wouters BG. Apoptosis, p53, and tumor cell sensitivity to anticancer agents. Cancer Res 1999;59:1391-9.
80. Rasey JS, Nelson NJ, Mahler P, et al. Radioprotection of normal tissues against gamma rays and cyclotron neutrons with WR-2721: LD50 studies and 35S-WR-2721 biodistribution. Radiat Res 1984;97:598-607.
81. Cassatt DR, Fazenbaker CA, Bachy CM, et al. Preclinical modeling of improved amifostine (Ethyol) use in radiation therapy. Semin Radiat Oncol 2002;12(Suppl 1):97-102.
82. Rubio-Viqueira B, Hidalgo M. Direct in vivo xenograft tumor model for predicting chemotherapeutic drug response in cancer patients. Clin Pharmacol Ther 2009;85:217-21.
83. Murgo AJ, Kummar S, Rubinstein L, et al. Designing phase 0 cancer clinical trials. Clin Cancer Res 2008;14:3675-82.